ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Consumer Discretionary / MRM / financials
OCG (42) PMAX (49) EJH (35) JWEL (40) ⌘ Pro Terminal →

MEDIROM Healthcare Technologies Inc. (MRM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.33 -4.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.33

MEDIROM Healthcare Technologies Inc. (MRM) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →
ROARABLE D • SELL / AVOID Cap $2.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MRM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MRM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $0.33 (-4.62% 1D, market cap $2.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1011 tracked Consumer Discretionary issuers, MRM ranks #552 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MRM compare to OCG and PMAX in the Consumer Discretionary sector?
▼

Within the Consumer Discretionary sector (Other Consumer Services), MRM carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OCG (Oriental Culture Holding LTD) holds a D- grade (42/100 RQD, P/E N/A, ROIC -9.4%, cap $3.2M) and PMAX (Powell Max Limited (Class A)) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $2.1M). Among the 5-stock peer group, MRM leads on earnings multiple (N/A) while OCG leads on capital efficiency (-9.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MRM?
▼

For MEDIROM Healthcare Technologies Inc. (MRM), key quantitative strengths include Established market leader in Consumer Discretionary with deep daily trading liquidity. and sector rank #552 in Consumer Discretionary, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.33 (-1.02%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Cash (12)Whales (6)SEC (13)Macro (11)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE MRM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MRM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY MRM SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($76.6K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
59
Grade C$0.54-33.3% Next Q
Q2 (-2Q)
56
Grade C$0.36+0% Next Q
Q3 (-1Q)
54
Grade C-$0.36-8.3% Next Q
Current
51
Grade D$0.33-1.3% Hist 90D α
Trajectory: C (59) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MRM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MRM currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Consumer Discretionary with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.65) and Max Pain ($0.35) forces dealer call-delta covering toward $2.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MRM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MRM Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How MRM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$76.6K (0% FCF Margin)
Revenue$4.00BGross Profit $2.08B (52%)Cost of Sales $1.92BOp Profit $1.08B (27%)OpEx (R&D/SG&A) $998.4MNet Profit$865.3M (21.6%)Tax/Other $216.3M
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MRM)

  • ✓Walkthrough of MRM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MRM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -72.95%▼ DESCENDING CHANNEL
2026-11-02O $0.36H $0.36L $0.33C $0.33VOL 16.3K
RES: $0.90SUP: $0.12SMA50: $0.65SMA200: $1.04
$1.82$1.40$0.97$0.54$0.12RES $0.90SUP $0.12$0.332026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MRM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MRM Butterfly Map → + Track MRM →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MRM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MRM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MRM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MRM)

Consumer Discretionary Rank #552 of 1011 ⚔️ OCG vs MRM Full Matrix →

1. Head-to-Head Consumer Discretionary Peer Comparison (MRM vs. OCG, PMAX, EJH, JWEL)

Industry: Other Consumer Services (73 Tracked Issuers)

Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, MEDIROM Healthcare Technologies Inc. (MRM) ranks #552 by composite RQD confidence (51/100, grade D) and #988 by equity capitalization ($2.7M). Within this direct 5-issuer industry benchmark cohort, MRM leads on earnings valuation at N/A trailing P/E, while OCG leads on capital efficiency and profitability with -9.4% ROIC and 85.7% gross margin. MRM currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MRM ACTIVE
MEDIROM Healthcare Technologies Inc.
D 51/100 — — — -4.62% $2.7M Benchmark Subject
OCG
Oriental Culture Holding LTD
D- 42/100 — 85.7% -9.4% -1.84% $3.2M /ocg-vs-mrm →
PMAX
Powell Max Limited (Class A)
D 49/100 — — — -6.18% $2.1M /pmax-vs-mrm →
EJH
E-Home Household Service Holdings Limited
D- 35/100 — 22.4% — -0.76% $4.2M /ejh-vs-mrm →
JWEL
Jowell Global Ltd.
D- 40/100 — — -35.0% -1.39% $5.1M /jwel-vs-mrm →

2. MRM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

MEDIROM Healthcare Technologies Inc. (MRM) operates in Other Consumer Services (Consumer Discretionary) with an equity capitalization of $2.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. MRM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MRM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $0.33 (-4.62% 1D, market cap $2.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1011 tracked Consumer Discretionary issuers, MRM ranks #552 in composite RQD confidence.

How does MRM compare to OCG and PMAX in the Consumer Discretionary sector?

Within the Consumer Discretionary sector (Other Consumer Services), MRM carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OCG (Oriental Culture Holding LTD) holds a D- grade (42/100 RQD, P/E N/A, ROIC -9.4%, cap $3.2M) and PMAX (Powell Max Limited (Class A)) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $2.1M). Among the 5-stock peer group, MRM leads on earnings multiple (N/A) while OCG leads on capital efficiency (-9.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MRM?

For MEDIROM Healthcare Technologies Inc. (MRM), key quantitative strengths include Established market leader in Consumer Discretionary with deep daily trading liquidity. and sector rank #552 in Consumer Discretionary, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MRM trading relative to its 50-day, 200-day, and 52-week technical levels?

MRM last traded at $0.33 (-4.62% on volume of 19,083 shares), positioning the stock -49.23% below its 50-day simple moving average ($0.65) and -68.27% below its 200-day simple moving average ($1.04). Across its 52-week range of $0.25 to $2.33, MRM sits at the 3.8% percentile with a 14-day RSI of 28.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.37).

MRM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is MEDIROM Healthcare Technologies Inc. (MRM)?

In Trailing 12 Months, MRM converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $76554 in free cash flow (0% FCF margin).

Direct Sub-Reports: MRM RQD Cockpit MRM 12M Forecast MRM Earnings & Move MRM Dividends & DRIP MRM Insiders & 13F MRM Whale Options MRM Profit Sankey MRM News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MRM — MEDIROM Healthcare Technologies Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:20:42Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MRM scores 51 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine 12/20 (ROIC 0%; FCF yield 0%), Whale 13F Flow 6/20 (institutional accumulation and options positioning), Insider Conviction 9/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillars are the cash engine and institutional/insider flow, which together point to limited evidence of cash generation and little visible accumulation. The balance-sheet pillar is the strongest component, which suggests solvency signals are less concerning than earnings and flow signals. For a prospective investor, the rating highlights that any upside thesis would have to rest on catalysts rather than current cash returns, and that the stock's price of $0.35 and market capitalization of $2.7M imply a high-risk, small-capitalization profile. Valuation tradeoffs cannot be assessed on earnings multiples because P/E and EV/EBITDA are not available in source data.

Business

MEDIROM Healthcare Technologies Inc. is listed on NASDAQ under the ticker MRM. Per the profile, it operates in the Consumer Discretionary sector, within the Other Consumer Services industry. Not available in source data for products sold, customer base, or revenue model.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the headlines reference the following items, each tagged to MRM:

  • A Yahoo Finance seasonal returns chart item (light: YELLOW, MARKET WIRE).
  • A Stock Titan item (light: GREEN, CATALYST) stating that after 31 business days below $1, Medirom has time to regain compliance. This is the most material catalyst in the feed and bears on Nasdaq listing status.
  • A kalkine.ca item (light: YELLOW, MARKET WIRE) reporting a pre-market decline of 9.74%, raising the question of further selling.
  • A Kalkine item (light: YELLOW, MARKET WIRE) reporting a pre-market advance of 7%.
  • A Benzinga item (light: YELLOW, MARKET WIRE) listing Consumer Discretionary stocks moving in pre-market trading.
  • A Yahoo! Finance Canada seasonal returns chart item for a different issuer (light: YELLOW, MARKET WIRE).

Risk watch items: the Nasdaq compliance matter, the 52-week range of $0.25 to $2.33 indicating sharp price volatility, and pre-market price swings in both directions. Per the Butterfly Supply-Chain Graph, supply chain is NONE, there are no butterfly links, and there are no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply_chain is NONE, butterfly_links is empty, and proprietary_signals is empty. Upstream and downstream dependencies, sector correlations beyond the sector and industry classifications, and second-order bottlenecks are not available in source data.

Open Questions

  • What revenue, operating income, and cash flow have MRM reported in recent periods, given that financial data is absent from the source set?
  • What is the outcome and timeline of the Nasdaq compliance matter referenced in the news feed?
  • What are the company's products, customers, and revenue model, given that the business description is not available in source data?
  • What are the ownership levels of institutional and insider holders, given that holder data is absent?
  • What is the company's cash runway and debt maturity profile behind the reported Debt/Equity ratio of 0.5?

MRM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for MEDIROM Healthcare Technologies Inc. (MRM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MRM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MRM Bull vs. Bear Conversation Board — What's Your Call at $0.33?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MRM 🐻 50% BEARISH CONVICTION
1. Pick Your Side on MRM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $0.38 (+8.6%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MRM (D • RQD 51/100) a Buy at $0.35?

Welcome to the MRM (MEDIROM Healthcare Technologies Inc.) Roar Pit. Current RQD Composite is 51/100 (Roarable Sell — Underperform / Distribution Warning) in Other Consumer Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.26 (-25.7%)
Spot @ $0.35

Pump the brakes on MRM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MRM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless MEDIROM Healthcare Technologies Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.45 (+28.6%)
Spot @ $0.35

MRM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MRM, the market is fixating on short-term headline noise in Other Consumer Services and ignoring the balance sheet and cash flow trajectory. At $0.35 (52-wk range $0.25 - $2.33), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%